Orchestra BioMed Holdings, Inc.
OBIO
Positions held
Your positionsOBIO isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $344.40M | Enterprise value | $315.30M | Trailing P/E | — | Forward P/E | -3.79 |
| PEG | — | Price / book | 17.85 | Beta | 0.52 | Dividend yield | 0.00% |
| Revenue growth | -89.5% | Earnings growth | — | Gross margin | 99.5% | Operating margin | -254.0% |
| Profit margin | -1.8% | ROE | -4.0% | ROA | -45.7% | Debt / equity | 2.41 |
| Current ratio | 8.26 | Free cash flow | -$31.81M | Analyst recommendation | strong_buy | Mean target | $12.43 |
| 52w high | $6.50 | 52w low | $2.86 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | $0.1M | $30.9M | $0.9M | $0.8M | — |
| Op margin | -25404.5% | -20069.1% | 21.8% | -2359.2% | -2311.8% | — |
| Net income | -$23.8M | -$20.7M | $6.2M | -$20.8M | -$19.4M | — |
| Gross margin | 71.6% | 70.9% | 99.8% | 94.3% | 94.5% | — |
| Gross profit | $0.1M | $0.1M | $30.9M | $0.8M | $0.8M | — |
| Operating income | -$22.4M | -$22.1M | $6.8M | -$20.3M | -$19.3M | — |
- Revenue -20% vs prior quarter ($0.1M vs $0.1M).
- Gross margin 71.6% (was 70.9% prior quarter).
- Operating margin compressed to -25404.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $33.5M | $2.6M | $2.8M | $3.5M | — |
| Op margin | -154.7% | -2437.5% | -1866.2% | -924.3% | — |
| Net income | -$52.7M | -$61.0M | -$49.1M | -$33.6M | — |
| Gross margin | 99.4% | 92.3% | 93.3% | 94.0% | — |
| Gross profit | $33.3M | $2.4M | $2.6M | $3.3M | — |
| Operating income | -$51.8M | -$64.3M | -$51.5M | -$32.7M | — |
Headlines — positive tone
• [OK · fundamentals] Orchestra BioMed Shares Rise After BTIG Upgrade
News
2026-10-01 · Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
2026-09-21 · Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
2026-09-16 · Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
2026-09-15 · Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
2026-09-15 · B. Riley Adjusts Orchestra BioMed Price Target to $11 From $10, Maintains Buy Rating
2026-09-10 · Orchestra BioMed Shares Rise After BTIG Upgrade
2026-09-10 · BTIG Upgrades Orchestra BioMed to Buy From Neutral, Price Target is $10
2026-09-02 · Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-27 · Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-20 · Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
2026-08-10 · Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates
2026-08-10 · Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Price (daily)
Full chart · RSI · MACD · patterns